You are here
Cancer groups challenge NICE ruling on Vidaza drug.
Cancer groups challenge NICE ruling on Vidaza drug.
Some MDS patients develop an aggressive form of leukaemia
Cancer groups are to appeal against a ruling which would deny NHS patients in England and Wales a drug for treating life-threatening bone marrow diseases.
The drug, Vidaza, gives patients with myelodysplastic syndromes (MDS) an extra nine months of life on average.
But the National Institute for Health and Clinical Excellence (NICE) ruled that Vidaza is too costly, relative to the benefits it brings.
The drug costs £45,000 a year per patient.